VANCOUVER, Feb. 4, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex")
(OTCQB: AVXL) is pleased to announce that it has retained specialized
intellectual property law firm Novak Druce Connolly Bove & Quigg LLP
("Novak Druce") to assist in maximizing the value of the company's
intellectual property (IP) portfolio. One of the largest IP boutique
firms in the United States, Novak Druce is renowned for its
entrepreneurial edge and commitment to proactive IP portfolio
"We believe that Anavex has discovered a class of therapeutic small
molecules active in diseases of the central nervous system, including
Alzheimer's, and cancer. Anavex is pursuing patent protection for
these molecules and treatments," said Tom Skarpelos, director of
Anavex. "Intellectual property, patents and proprietary technology
rights are important cornerstones for any pharmaceutical company. As
such, we intend to leverage these assets developing core therapeutics
and out-licensing ancillary aspects."
"Sound intellectual property is central to drug development and
commercialization," said Thomas M. Saunders of Novak Druce. "We will
assist Anavex in a rigorous approach to creating and maintaining its
patent portfolio and we are pleased to be working with the company to
maximize these assets."
Mr. Saunders specializes in representing emerging pharmaceutical,
medical technology and biotechnology concerns and addressing IP
licensing. He has advised on intellectual property strategy
development, patent portfolio preparation and management, and strategic
partnering evaluation for more than 20 years. Mr. Saunders has a
substantial background in biotechnology and chemical patent practice,
facilitated by his graduate studies in physiology at Case Western
Reserve University and Albany Medical College.
Anavex owns two U.S. patent applications, USSN 12/522,761 and USSN
13/201,271, and additional counterpart international patent
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug
candidates. ANAVEX 2-73, a drug candidate developed to treat
Alzheimer's disease through disease modification, has undergone an
initial Phase 1 human clinical trial and was well tolerated in doses up
to 55mg. Sponsored pre-clinical studies indicate that ANAVEX 2-73
demonstrates anti-amnesic and neuroprotective properties. Anavex is a
publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery and development, which include, without limitation, the
potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to finance development or satisfy the rigorous
regulatory requirements for new drugs, our ability to attract and
retain quality personnel, and that despite positive results, our
competitors may offer better or cheaper alternatives. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092
SOURCE Anavex Life Sciences Corp.